Corpus Intelligence IC Memo — SSH - ERIE 2026-04-26 09:35 UTC
IC Memo — SSH - ERIE
Investment Committee Memorandum | PA | 50 beds | Grade D | EBITDA uplift $1.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SSH - ERIE

CCN 392037 | ERIE, PA | 50 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

SSH - ERIE is a 50-bed community hospital in ERIE, PA with $15.3M in net patient revenue and a 1.9% operating margin. The hospital serves a payer mix of 34.0% Medicare, 0.0% Medicaid, and 66.0% commercial.

Thesis: Turnaround. Our ML models identify $1.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 1.9% to 9.2% (+736bps).

Net Revenue HCRIS$15.3M
Current EBITDA COMPUTED$288K
Operating Margin COMPUTED1.9%
Occupancy HCRIS42.5%
Revenue / Bed COMPUTED$305K
Net-to-Gross HCRIS14.2%
Distress Probability MLnan%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
90
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of 1.9% places it above the state median. Among 90 size-comparable peers (25-100 beds), the median margin is 0.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (25-100), prioritizing same-state peers. 90 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SSH - ERIE (Target)PA50$15.3M1.9%
THE GETTYSBURG HOSPITALPA76$341.8M18.4%
AMERICAN ONCOLOGIC HOSPIALPA100$229.8M-11.1%
ST. LUKES HOSPITAL - MONROE CAPA98$221.8M7.8%
UPMC HANOVERPA73$200.8M18.2%
MEMORIAL HOSPITALPA80$184.5M13.1%
UPMC CARLISLEPA72$165.0M19.5%
UPMC HORIZON HOSPITALPA99$156.4M-16.5%
OSS ORTHOPAEDIC HOSPITALPA30$149.4M-5.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$321K+210bp18mo
Cost to Collect4.5%2.5%$305K+200bp12mo
Denial Rate Reduction12.0%6.5%$302K+198bp12mo
A/R Days Reduction5200.0%3800.0%$186K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$321K
Cost to Collect
$305K
Denial Rate Reduction
$302K
A/R Days Reduction
$186K
Clean Claim Rate
$10K
Total EBITDA Uplift$1.1M
Current EBITDA$288K
+ RCM Uplift+$1.1M
Pro Forma EBITDA$1.4M
Current Margin1.9%
Pro Forma Margin9.2%
WC Released (1x)$586K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$443K$13.1M29.68x97.0%
Base (11x exit)10.0x11.0x$443K$14.6M32.97x101.2%
Bull Case9.0x11.0x$399K$18.5M46.30x115.3%
Bull (12x exit)9.0x12.0x$399K$20.2M50.81x119.4%
Bear Case11.0x10.0x$487K$7.4M15.14x72.2%
Bear (11x exit)11.0x11.0x$487K$8.3M16.98x76.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 90 hospitals with 25-100 beds
  • Same-state prioritization (n=91)
  • Comp margins: P25=-16.5% / P50=0.1% / P75=8.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.